Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells $227,600.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $45.52, for a total value of $227,600.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $590,166.80. The trade was a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Amy Bachrodt also recently made the following trade(s):

• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00.
• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00.
• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $43.36 on Thursday. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $47.36. The firm has a market capitalization of $2.09 billion and a P/E ratio of -2.07. The company’s 50 day simple moving average is $40.52 and its 200 day simple moving average is $28.67.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Legal & General Group Plc raised its position in Maze Therapeutics by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after buying an additional 977 shares during the last quarter. Bank of America Corp DE lifted its stake in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after acquiring an additional 1,455 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price for the company. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wedbush boosted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Guggenheim restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $44.50.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.